Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00956969
Other study ID # WSU0000001
Secondary ID
Status Completed
Phase N/A
First received August 10, 2009
Last updated June 13, 2013
Start date September 2009
Est. completion date May 2011

Study information

Verified date June 2013
Source Wayne State University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This interventional, randomized controlled study seeks to test the effects of a novel emotional awareness and expression intervention against relaxation training or no intervention for college students with chronic headaches. These two interventions are conceptually quite distinct, as the former seeks to activate and process anger, whereas the latter, more commonly used technique, seeks to suppress or avoid it.


Recruitment information / eligibility

Status Completed
Enrollment 147
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Undergraduate students at Wayne State University who have chronic headaches

Exclusion Criteria:

- Insufficiently frequent headaches

- Uninterested in engaging in a stress management intervention

- Headaches appear due to substance use or head trauma

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Anger Awareness and Expression
Teaches patients to recognize, experience, and express emotions
Relaxation Training
Teaches patients relaxation training

Locations

Country Name City State
United States Wayne State University Detroit Michigan

Sponsors (1)

Lead Sponsor Collaborator
Wayne State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Headache frequency and severity baseline, 6-weeks, 6-months No
Secondary Headache disability baseline, 6-weeks, 6-months No
Secondary Mood, self-efficacy, stress symptoms baseline and 6-weeks No
See also
  Status Clinical Trial Phase
Completed NCT02270177 - Telemedicine Versus Traditional Specialist Consultation for Headache: a Non-inferiority Trial N/A
Completed NCT00475189 - Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills) N/A
Terminated NCT02638506 - RCT Evaluating Intranasal Fentanyl in the Pain Management of Children With Headaches Phase 4
Completed NCT00484029 - Nasal Carbon Dioxide (CO2)for the Treatment of Temporomandibular Disorders (TMD)Related Pain Phase 2
Completed NCT01667679 - Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Phase 3
Completed NCT00921453 - Tailored Internet Information Supply for Patients - Part 2 N/A
Completed NCT00067249 - Women's Use of Alternative Medicine: A Multiethnic Study N/A